PRODUCTS & INNOVATION
We've shaped our business to always stay true to our fundamental goal.
Jan 21 2020
Abbott has a robust and rich heritage that has helped us remain relevant for more than 130 years.
We’ve shaped our businesses to always stay true to our fundamental goal – to help people live longer and live better.
As we kick off a new decade, Abbott President and Chief Operating Officer – and soon-to-be Chief Executive Officer – Robert F. Ford reminded J.P. Morgan Healthcare Conference attendees that Abbott is now bigger, stronger, more balanced and better positioned than ever.
“Our goal has always been to position Abbott as a growth company,” Ford said at the conference. “The key strategic framework behind that sustainable growth is a philosophy of always looking ahead, anticipating where medical technology and medical needs will be so that we can be relevant and be sustainable.”
We have an established track record of delivering double-digit EPS growth and organic sales growth in the 7-8% range. An important part of our foundation comes from the leadership positions we hold across many large, attractive and fast-growing markets. We’ve sustained those leadership positions by delivering life-changing innovation to people with some of the world’s most prevalent healthcare conditions, such as diabetes, heart disease and the constant need for more accurate and timely test results.
For example, Abbott's FreeStyle Libre portfolio reflects the power of making medical devices simpler. With FreeStyle Libre users roughly doubling each year, the device has helped make it much easier for people living with diabetes to monitor their glucose levels – and it’s priced for broad adoption.
Another solid growth area for Abbott continues to be diagnostics. Our Alinity family of diagnostic instruments, which was engineered to be faster and simpler to operate within a smaller footprint, continues to rollout. As Alinity penetrates new markets and wins renewals with established customers, the benefits for Abbott's performance will continue to grow.
Heart health continues to also dominate healthcare challenges. Among our key innovations in Abbott's Structural Heart portfolio – is MitraClip, a minimally-invasive treatment for mitral regurgitation, or a leaky heart valve. In early 2019, this device received an expanded indication for use in people with significant or severe secondary mitral regurgitation help treat even more people. And earlier this month, we initiated a trial to study MitraClip as an option for moderate surgical risk patients – potentially expanding the patient population even further.
These key technologies, a steady cadence of product approvals and strategic execution have provided a great foundation for strong, sustainable growth.
“We’ve reshaped our company for the long run, and we’ve aligned to the most pressing medical needs,” Ford said. “We’ve had a history of setting ambitious goals and a culture of accountability to meeting those targets.”
Indications and Important Safety Information
FreeStyle Libre and FreeStyle Libre 14 day Flash Glucose Monitoring systems are continuous glucose monitoring (CGM) devices indicated for replacing blood glucose testing and detecting trends and tracking patterns aiding in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments in persons (age 18 and older) with diabetes. The systems are intended for single patient use and require a prescription.
CONTRAINDICATIONS: Remove the sensor before MRI, CT scan, X-ray, or diathermy treatment.
WARNINGS/LIMITATIONS: Do not ignore symptoms that may be due to low or high blood glucose, hypoglycemic unawareness, or dehydration. Check sensor glucose readings with a blood glucose meter when Check Blood Glucose symbol appears, when symptoms do not match system readings, or when readings are suspected to be inaccurate. The system does not have alarms unless the sensor is scanned, and the system contains small parts that may be dangerous if swallowed. The system is not approved for pregnant women, persons on dialysis, or critically-ill population. Sensor placement is not approved for sites other than the back of the arm and standard precautions for transmission of blood borne pathogens should be taken. The built-in blood glucose meter is not for use on dehydrated, hypotensive, in shock, hyperglycemic-hyperosmolar state, with or without ketosis, neonates, critically-ill patients, or for diagnosis or screening of diabetes. When using FreeStyle LibreLink app, access to a blood glucose monitoring system is required as the app does not provide one. Review all product information before use or contact Abbott Toll Free (855-632-8658) or visit www.freestylelibre.us for detailed indications for use and safety information.
Abbott Reports Q1 Earnings
Abbott Posts Strong 2019 Results
Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
The website you have requested also may not be optimized for your specific screen size.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.
The website that you have requested also may not be optimized for your screen size.